BillionToOne, Inc.
BLLN
Rangering i aksjer
#3474
BillionToOne, Inc. is a specialized diagnostics company that innovates by... BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Aksjekurs
$105.11
Sist synkronisert: 2026-10-21
Markedsverdi
$4.96B
Endring (1 dag)
1.56%
Endring (1 år)
-
Land
US
Handel BillionToOne, Inc. (BLLN)
Kategori
Healthcare
EPS for BillionToOne, Inc. (BLLN)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til BillionToOne, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for BillionToOne, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $18.62 | - |
US
|
|
| $5.65 | - |
US
|
|
| $-1.36 | - |
US
|
|
| - | - |
CN
|
|
| $5.09 | - |
US
|
